Agency Forms Undergoing Paperwork Reduction Act Review, 75257-75258 [E6-21273]
Download as PDF
<![CDATA[
75257
Federal Register / Vol. 71, No. 240 / Thursday, December 14, 2006 / Notices
died (Morbidity and Mortality Weekly
Report 2003;52[31]:735–9). A severe
adverse event is defined as
hospitalization or death of a person
receiving treatment for LTBI. On the
basis of these data, the American
Thoracic Society and CDC
recommended that RZ should generally
not be offered for treatment of persons
with LTBI, regardless of HIV status.
Rifampin and pyrazinamide should
continue to be administered in
multidrug regimens for the treatment of
persons with active TB disease.
Reports of severe adverse events
related to RZ and other older LTBI
regimens have prompted a need for this
three year project—a national
surveillance system of such events. The
objective of the project is to determine
the annual number and temporal trends
of severe adverse events (hospitalization
or death) associated with any treatment
for LTBI in the United States.
treatment of LTBI and contains
demographic, clinical, and laboratory
information. CDC will analyze and
periodically publish reports
summarizing national LTBI treatment
adverse events statistics and also will
conduct special analyses for publication
in peer-reviewed scientific journals to
further describe and interpret these
data.
The Food and Drug Administration
(FDA) collects data on adverse events
related to drugs through the FDA
MedWatch Program. CDC is planning to
collaborate with FDA in developing the
national surveillance system for adverse
events associated with treatment for
LTBI. Reporting will be conducted
through telephone, e-mail, or during
CDC site visits. The only cost to
respondents is their time to gather
medical records to complete the form.
Surveillance of such events will provide
data to support periodic evaluation of
guidelines for treatment of persons with
LTBI and revision, as needed.
This project will set up a passive
reporting system for severe adverse
events (death or hospitalization) to
therapy for LTBI. The system will rely
on medical chart review of already
existing data by TB control staff.
Potential respondents are any of the
60 reporting areas for the national TB
surveillance system (the 50 states, the
District of Columbia, New York City,
Puerto Rico, and 8 jurisdictions in the
Pacific and Caribbean). Data will be
collected using the data collection form
for adverse events associated with LTBI
treatment (AELT). Based on previous
reporting, CDC anticipates receiving an
average of 3 responses per year from the
60 reporting areas. The AELT form is
completed for each reported
hospitalization or death related to
ESTIMATE OF ANNUALIZED BURDEN HOURS
Average burden per response
(in hours)
Number of respondents
Number of responses per
respondent
Physicians ........................................................................................................
Nurses ..............................................................................................................
Medical Clerk ...................................................................................................
3
3
3
1
1
1
3
4
1
9
12
3
Total ..........................................................................................................
........................
........................
........................
24
Type of respondents
Dated: December 8, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E6–21269 Filed 12–13–06; 8:45 am]
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–6974. Written
comments should be received within 30
days of this notice.
BILLING CODE 4163–18–P
Proposed Project
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30 Day–07–0128]
rwilkins on PROD1PC63 with NOTICES
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
VerDate Aug<31>2005
17:54 Dec 13, 2006
Jkt 211000
Congenital Syphilis (CS) Case
Investigation and Report Form
(CDC73.126)—OMB No. 0920–0128—
Extension—National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Coordinating
Center for Infectious Diseases (CCID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
CDC proposes to continue data
collection for congenital syphilis case
investigations under the ‘‘Congenital
Syphilis (CS) Case Investigation and
Report Form’’ (CDC73.126, REV 10–
2003). This form is currently approved
under OMB No. 0920–0128, and is due
to expire on 12/31/2006. This request is
for a 3-year extension of OMB approval.
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
Total burden
(in hours)
Reducing congenital syphilis is a
national objective in the DHHS Report
entitled Healthy People 2010 (Vol. I and
II). Objective 25–9 of this document
states the goal: ‘‘Reduce congenital
syphilis to 1 new case per 100,000 live
births’’. In order to meet this national
objective, an effective surveillance
system for congenital syphilis must be
continued to monitor current levels of
disease and progress towards the year
2010 objective. This data will also be
used to develop intervention strategies
and to evaluate ongoing control efforts.
Respondent burden is approximately
15 minutes per response for those who
provide data electronically and 30
minutes per response for those who
provide data via hard copy. The
estimated annual number of cases
expected to be reported using the
current case definition is approximately
500. There are no costs to the
respondents other than their time. The
total estimated annual burden hours are
160.
E:\FR\FM\14DEN1.SGM
14DEN1
75258
Federal Register / Vol. 71, No. 240 / Thursday, December 14, 2006 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of respondents
Respondents
Clerical and hospital staff of state and local health department STD project
areas ............................................................................................................
Average number of responses per
respondent
50
(electronic
data)
15
(hardcopy
data)
Average burden per response
(in hours)
Total burden
(in hours)
8
15/60
100
8
30/60
60
Dated: December 7, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E6–21273 Filed 12–13–06; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
not a toll-free number). Information
requests can also be submitted by e-mail
to OCAS@CDC.GOV.
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
Decision To Evaluate a Petition To
Designate a Class of Employees at
Dow Chemical Company, Madison, IL,
To Be Included in the Special
Exposure Cohort
Dated: December 7, 2006.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 06–9668 Filed 12–13–06; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
AGENCY:
Mine Safety and Health Research
Advisory Committee: Notice of Charter
Renewal
rwilkins on PROD1PC63 with NOTICES
This gives notice under the Federal
Advisory Committee Act (Public Law
92–463) of October 6, 1972, that the
Mine Safety and Health Research
Advisory Committee, Centers for
Disease Control and Prevention,
Department of Health and Human
Services, has been renewed for a 2-year
period through November 30, 2008.
For information, contact Jeffrey
Kohler, Ph.D., Executive Secretary,
Mine Safety and Health Research
Advisory Committee, Centers for
Disease Control and Prevention,
Department of Health and Human
Services, 626 Cochrans Mill Road,
Mailstop P05, Pittsburgh, Pennsylvania
15236, telephone 412/386–5301 or fax
404/386–5300.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: December 8, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–21264 Filed 12–13–06; 8:45 am]
BILLING CODE 4163–18–P
VerDate Aug<31>2005
17:54 Dec 13, 2006
Jkt 211000
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
BILLING CODE 4163–19–M
The Department of Health and
Human Services (HHS) gives notice as
required by 42 CFR § 83.12(e) of a
decision to evaluate a petition to
designate a class of employees at Dow
Chemical Company, Madison, Illinois,
to be included in the Special Exposure
Cohort under the Energy Employees
Occupational Illness Compensation
Program Act of 2000. The initial
proposed definition for the class being
evaluated, subject to revision as
warranted by the evaluation, is as
follows:
Facility: Dow Chemical Company.
Location: Madison, Illinois.
Job Titles and/or Job Duties: All
Atomic Weapons Employer employees
who were monitored, or should have
been monitored, for exposure to
ionizing radiation while working for a
number of work days aggregating at least
250 work days, either solely under this
employment or in combination with
work days within the parameters
established for one or more other classes
of employees in the Special Exposure
Cohort.
Period of Employment: January 1,
1957 through December 21, 1960.
FOR FURTHER INFORMATION CONTACT:
Larry Elliott, Director, Office of
Compensation Analysis and Support,
National Institute for Occupational
Safety and Health, 4676 Columbia
Parkway, MS C–46, Cincinnati, OH
45226, Telephone 513–533–6800 (this is
SUMMARY:
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Peptide and Peptidomimetic Inhibitors
of Smoothened Protein as Antineoplastic Agents
Description of Technology: Cancer is
caused by the improper regulation of
certain signaling proteins in the cell.
E:\FR\FM\14DEN1.SGM
14DEN1
]]>Agencies
[Federal Register Volume 71, Number 240 (Thursday, December 14, 2006)]
[Notices]
[Pages 75257-75258]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-21273]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30 Day-07-0128]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-5960 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-6974.
Written comments should be received within 30 days of this notice.
Proposed Project
Congenital Syphilis (CS) Case Investigation and Report Form
(CDC73.126)--OMB No. 0920-0128--Extension--National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Coordinating
Center for Infectious Diseases (CCID), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
CDC proposes to continue data collection for congenital syphilis
case investigations under the ``Congenital Syphilis (CS) Case
Investigation and Report Form'' (CDC73.126, REV 10-2003). This form is
currently approved under OMB No. 0920-0128, and is due to expire on 12/
31/2006. This request is for a 3-year extension of OMB approval.
Reducing congenital syphilis is a national objective in the DHHS
Report entitled Healthy People 2010 (Vol. I and II). Objective 25-9 of
this document states the goal: ``Reduce congenital syphilis to 1 new
case per 100,000 live births''. In order to meet this national
objective, an effective surveillance system for congenital syphilis
must be continued to monitor current levels of disease and progress
towards the year 2010 objective. This data will also be used to develop
intervention strategies and to evaluate ongoing control efforts.
Respondent burden is approximately 15 minutes per response for
those who provide data electronically and 30 minutes per response for
those who provide data via hard copy. The estimated annual number of
cases expected to be reported using the current case definition is
approximately 500. There are no costs to the respondents other than
their time. The total estimated annual burden hours are 160.
[[Page 75258]]
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average number Average burden
Respondents Number of of responses per response Total burden
respondents per respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Clerical and hospital staff of state and local 50 8 15/60 100
health department STD project areas............ (electronic
data)
15 8 30/60 60
(hardcopy
data)
----------------------------------------------------------------------------------------------------------------
Dated: December 7, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E6-21273 Filed 12-13-06; 8:45 am]
BILLING CODE 4163-18-P
